ReviewACS synthetic biology2024
Perspectives on Genetically Engineered Microorganisms and Their Regulation in the United States.
Review in ACS synthetic biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Resilience of recombinant antibiotic resistance gene-containing plasmids against common cell culture disposal methods.Cell reports methods · 2026Article
- Engineering Plant-Associated Microorganisms for Bioremediation and Sustainable Agriculture.Microorganisms · 2026Review
- An engineered Pseudomonas stutzeri strain overexpressing the sigma factor AlgU promotes maize growth under salt stress.Applied microbiology and biotechnology · 2026Article
- From lab to law: emerging applications, potential benefits, evolving regulatory framework and challenges for engineered probiotics.Microbial cell factories · 2026Review
- Advancing climate-resilient livestock systems: Next-generation emission mitigation strategies and integrated technological innovations.Veterinary and animal science · 2026Review
- Genetically Modified Microorganisms: Risks and Regulatory Considerations for Human and Environmental Health.Microorganisms · 2026Review
- Insects as a New Source of Plant Growth Promoting Bacteria - Review.Microbial ecology · 2026Review
- Engaging U.S. experts in environmental oversight of GE crops as it relates to novel biotechnologies.Frontiers in bioengineering and biotechnology · 2026Article
- Microbial technologies as an ecological tool for advancing environmental sustainability.Frontiers in microbiology · 2026Review
- Engineering of Synthetic Microbial Consortia for Sustainable Management of Wastewater and Polyethylene Terephthalate: A Comprehensive Review.International journal of molecular sciences · 2025Review
- Recent trends in microbial production of alkanes.World journal of microbiology & biotechnology · 2025Review
- Genetic "expiry-date" circuits control lifespan of synthetic scavenger bacteria for safe bioremediation.Nucleic acids research · 2025Article
- Environmental Applications of GM Microorganisms: Tiny Critters Posing Huge Challenges for Risk Assessment and Governance.International journal of molecular sciences · 2025Review
- Engineering Useful Microbial Species for Pharmaceutical Applications.Microorganisms · 2025Review
- Effects of Microorganisms in Fish Aquaculture from a Sustainable Approach: A Review.Microorganisms · 2025Review
- The current increase and future perspectives of the microbial pesticides market in agriculture: the Brazilian example.Frontiers in microbiology · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetically engineered microorganisms (GEMs) represent a new paradigm in our ability to address the needs of a growing, changing world. GEMs are being used in agriculture, food production and additives, manufacturing, commodity and noncommodity products, environmental remediation, etc., with even more applications in the pipeline. Along with modern advances in genome-manipulating technologies, new manufacturing processes, markets, and attitudes are driving a boom in more products that contain or are derived from GEMs. Consequentially, researchers and developers are poised to interact with biotechnology regulatory policies that have been in effect for decades, but which are out of pace with rapidly changing scientific advances and knowledge. In the United States, biotechnology is regulated by multiple agencies with overlapping responsibilities. This poses a challenge for both developers and regulators to simultaneously allow new innovation and products into the market while also ensuring their safety and efficacy for the public and environment. This article attempts to highlight the various factors that interact between regulatory policy and development of GEMs in the United States, with perspectives from both regulators and developers. We present insights from a 2022 workshop hosted at the University of California, Berkeley that convened regulators from U.S. regulatory agencies and industry developers of various GEMs and GEM-derived products. We highlight several new biotechnologies and applications that are driving innovation in this space, and how regulatory agencies evaluate and assess these products according to current policies. Additionally, we describe recent updates to regulations that incorporate new technology and knowledge and how they can adapt further to effectively continue regulating for the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.